Mitesh J Borad MD

Assistant Professor of Medicine Mayo Clinic

13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000

Dr. Borad is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Borad's full profile Already have an account?

Education & Training

Tulane UniversityFellowship, Hematology and Medical Oncology, 2003 - 2005
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2000 - 2003
Rutgers New Jersey Medical SchoolClass of 2000

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2001 - Present
AZ State Medical License 2005 - 2027
LA State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification FirstNet (Image Results), Cerner Corporation, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and FirstNet, Cerner Corporation, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Corporation, 2014-2015, 2017

Clinical Trials

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
COMPLETED
PHASE1, PHASE2
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
COMPLETED
PHASE2
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
COMPLETED
PHASE1

Publications & Presentations

PubMed

Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target.
Dong-Gi Mun, Erik Jessen, Jennifer L Tomlinson, Danielle Carlson, Rohit Budhraja
Hepatology. 2026-08-01
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
Eileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, Mitesh J Borad, Filippo Pietrantonio
The New England Journal of Medicine. 2026-07-23
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.
Priyanshi Shah, Anina Peersen, Vaibhav Sahai, Amit Mahipal, Nikolas Naleid
JCO Precision Oncology. 2026-07-01

Journal Articles

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Mohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases
Mitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
Chromoanasynthesis Is a Common Mechanism That Leads to ERBB2 Amplifications in a Cohort of Early Stage HER2+ Breast Cancer Samples
Katherine B Geiersbach, Mitesh J Borad, Sarah A McLaughlin, BioMed Central

Lectures

A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) chol...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Clinical Hematology and Oncology 2013: The 10th Annual Mayo Board Review
Mayo School of Continuous Professional Development, Scottsdale, Arizona - 1/18/2013

Press Mentions

‘The Most Significant Change in 20 Years’: Cancer Centers Prepare for Daraxonrasib DemandMay 29th, 2026
RedHill Teams with Mayo Clinic, MD Anderson on New Cancer TrialDecember 28th, 2017